J Clin Med. 2016 Jul 27;5(8). pii: E67.
Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data
Bozzatello P1, Brignolo E2, De Grandi E3, Bellino S4.
Author information
- 1Centre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. paola.bozzatello@unito.it
- 2Centre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. elena.brignolo@yahoo.com
- 3Centre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. elisa.degrandi@gmail.com
- 4Centre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. silvio.bellino@unito.it
Abstract
A
new application for omega-3 fatty acids has recently emerged,
concerning the treatment of several mental disorders. This indication is
supported by data of neurobiological research, as highly unsaturated
fatty acids (HUFAs) are highly concentrated in neural phospholipids and
are important components of the neuronal cell membrane. They modulate
the mechanisms of brain cell signaling, including the dopaminergic and
serotonergic pathways. The aim of this review is to provide a complete
and updated account of the empirical evidence of the efficacy and safety
that are currently available for omega-3 fatty acids in the treatment
of psychiatric disorders. The main evidence for the effectiveness of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been
obtained in mood disorders, in particular in the treatment of depressive
symptoms in unipolar and bipolar depression. There is some evidence to
support the use of omega-3 fatty acids in the treatment of conditions
characterized by a high level of impulsivity and aggression and
borderline personality disorders. In patients with attention deficit
hyperactivity disorder,
small-to-modest effects of omega-3 HUFAs have been found. The most
promising results have been reported by studies using high doses of EPA
or the association of omega-3 and omega-6 fatty acids. In schizophrenia,
current data are not conclusive and do not allow us either to refuse or
support the indication of omega-3 fatty acids.
For the remaining psychiatric disturbances, including autism spectrum disorders, anxiety disorders, obsessive-compulsive disorder, eating disorders and substance use disorder, the data are too scarce to draw any conclusion. Concerning tolerability, several studies concluded that omega-3 can be considered safe and well tolerated at doses up to 5 g/day.
Pour les troubles psychiatriques restants, y compris les troubles du spectre de l'autisme, les troubles anxieux, les troubles obsessionnels compulsifs, les troubles alimentaires et le trouble de la consommation de substances , les données sont trop rares pour en tirer une conclusion. En ce qui concerne la tolérance, plusieurs études ont conclu que les oméga-3 peut être considérés comme sûrs et bien tolérés à des doses allant jusqu'à 5 g / jour.
For the remaining psychiatric disturbances, including autism spectrum disorders, anxiety disorders, obsessive-compulsive disorder, eating disorders and substance use disorder, the data are too scarce to draw any conclusion. Concerning tolerability, several studies concluded that omega-3 can be considered safe and well tolerated at doses up to 5 g/day.
Pour les troubles psychiatriques restants, y compris les troubles du spectre de l'autisme, les troubles anxieux, les troubles obsessionnels compulsifs, les troubles alimentaires et le trouble de la consommation de substances , les données sont trop rares pour en tirer une conclusion. En ce qui concerne la tolérance, plusieurs études ont conclu que les oméga-3 peut être considérés comme sûrs et bien tolérés à des doses allant jusqu'à 5 g / jour.
- PMID: 27472373
Aucun commentaire:
Enregistrer un commentaire